Skip to main content
SpringerLink
Log in
Book cover

Chronic Lymphocytic Leukemia pp 219–240Cite as

Guidelines for Clinical Management of CLL

  • Chapter

Part of the book series: Contemporary Hematology ((CH))

Abstract

B-cell chronic lymphocytic leukemia (B-CLL), the most common form of leukemia in Western countries, results from the relentless accumulation of small, mature, slowly dividing, monoclonal B-lymphocytes (1). Affected patients are always adults: the median age at diagnosis is 64 yr. BCLL cells are characterized by coexpression of the pan-B -cell markers CD5 and CD23, negativity for CD22 and FMC7 molecules, and low expression of the B-cell receptor surface Ig and Igassociated molecule CD79b (2–4).

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Dighiero G, Travade P, Chevret S, Fenaux P, Chastang C, Binet JL. B-cell chronic lymphocytic leukemia: present status and future directions. French Cooperative Group on CLL. Blood 1991; 78: 1901–1914.

    PubMed  CAS  Google Scholar 

  2. Matutes E, Owusu-Ankomah K, Morilla R, et al. The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL. Leukemia 1994; 8: 1640–1645.

    PubMed  CAS  Google Scholar 

  3. Zomas AP, Matutes E, Morilla R, Owusu-Ankomah K, Seon BK, Catovsky D. Expression of the immunoglobulinassociated protein B29 in B cell disorders with the monoclonal antibody SN8 (CD79b). Leukemia 1996; 10: 1966–1970.

    PubMed  CAS  Google Scholar 

  4. Ternynck T, Dighiero G, Follezou J, Binet JL. Comparison of normal and CLL lymphocyte surface Ig determinants using peroxidase-labeled antibodies. I. Detection and quantitation of light chain determinants. Blood 1974; 43: 789–795.

    PubMed  CAS  Google Scholar 

  5. Conley CL, Misiti J, Laster AJ. Genetic factors predisposing to chronic lymphocytic leukemia and to autoimmune disease. Medicine 1980; 59: 323–334.

    Article  PubMed  CAS  Google Scholar 

  6. Linet MS, Van Natta ML, Brookmeyer R, et al. Familial cancer history and chronic lymphocytic leukemia. A case-control study. Am J Epidemiol 1989; 130: 655–664.

    PubMed  CAS  Google Scholar 

  7. Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS. Clinical staging of chronic lymphocytic leukemia. Blood 1975; 46: 219–234.

    PubMed  CAS  Google Scholar 

  8. Binet JL, Auquier A, Dighiero G, et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 1981; 48: 198–206.

    Article  PubMed  CAS  Google Scholar 

  9. French Cooperative Group on Chronic Lymphocytic Leukemia. Effects of chlorambucil and therapeutic decision in initial forms of chronic lymphocytic leukemia (stage A): results of a randomized clinical trial on 612 patients. Blood 1990; 75: 1414–1421.

    Google Scholar 

  10. Dighiero G, Maloum K, Desablens B, et al. Chlorambucil in indolent chronic lymphocytic leukemia. French Cooperative Group on Chronic Lymphocytic Leukemia. N Eng J Med 1998; 338: 1506–1514.

    Article  CAS  Google Scholar 

  11. Catovsky D, Fooks J, Richards S. The UK Medical Research Council CLL trials 1 and 2. Nouv Rev Fr Hematol 1988; 30: 423–427.

    PubMed  CAS  Google Scholar 

  12. Shustik C, Mick R, Silver R, Sawitsky A, Rai K, Shapiro L. Treatment of early chronic lymphocytic leukemia: intermittent chlorambucil versus observation. Hematol Oncol 1988; 6: 7–12.

    Article  PubMed  CAS  Google Scholar 

  13. Spanish Cooperative Group Pethema. Treatment of chronic lymphocytic leukemia: a preliminary report of Spanish (Pethema) trials. Leuk Lymphoma 1991; 5: 89–91.

    Google Scholar 

  14. CLL Trialists’ Collaborative Group. Chemotherapeutic options in chronic lymphocytic leukemia: a meta-analysis of the randomized trials. CLL Trialists’ Collaborative Group. J Natl Cancer Inst 1999; 91: 861–868.

    Google Scholar 

  15. Jaksic B, Brugiatelli M. High dose continuous chlorambucil vs intermittent chlorambucil plus prednisone for treatment of B-CLL-IGCI CLL-01 trial. Nouv Rev Fr Hematol 1988; 30: 437–442.

    PubMed  CAS  Google Scholar 

  16. French Cooperative Group on Chronic Lymphocytic Leukaemia. Natural history of stage A chronic lymphocytic leukaemia untreated patients. Br J Haematol 1990; 76: 45–57.

    Google Scholar 

  17. Montserrat E, Vinolas N, Reverter JC, Rozman C. Natural history of chronic lymphocytic leukemia: on the progression and prognosis of early clinical stages. Nouv Rev Fr Hematol 1988; 30: 359–361.

    PubMed  CAS  Google Scholar 

  18. Keating MJ, Lerner S, Kantarjian H, Freireich EJ, O’Brien S. The serum beta2-microglobulin (beta2M) level is more powerful than stage in predicting response and survival in chronic lymphocytic leukemia (CLL). Blood 1998; 86: 606a.

    Google Scholar 

  19. Sarfati M, Bron D, Lagneaux L, Fonteyn C, Frost H, Delespesse G. Elevation of IgE-binding factors in serum of patients with B cell-derived chronic lymphocytic leukemia. Blood 1988; 71: 94–98.

    PubMed  CAS  Google Scholar 

  20. Leotard S. Etude de la valeur pronostique du CD23 soluble dans la leucémie Lymphnoeud Chronique chez des patients en stade A, non traités. Comparaison avec la béta2-microglobuline, l’albumine et la LDH. These pour le diphime d’état de Docteur en Pharmacie. Université de Paris Sud, 1998.

    Google Scholar 

  21. Hallek M, Langenmayer I, Nerl C, et al. Elevated serum thymidine kinase levels identify a subgroup at high risk of disease progression in early, nonsmoldering chronic lymphocytic leukemia. Blood 1999; 93 (5): 1732–1737.

    PubMed  CAS  Google Scholar 

  22. Dohner H, Stilgebauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000; 343 (26): 1910–1916.

    Article  PubMed  CAS  Google Scholar 

  23. Schroeder HW, Jr., Dighiero G. The pathogenesis of chronic lymphocytic leukemia: analysis of the antibody repertoire. Immunol Today 1994; 15: 288–294.

    Article  PubMed  CAS  Google Scholar 

  24. Damle RN, Wasil T, Fais F, et al. Immunoglobulin V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999; 94: 1840–1848.

    PubMed  CAS  Google Scholar 

  25. Hamblin TJ, Davis Z, Oscier DG, Stevenson FK. Unmutated immunoglobulin VH genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999; 94: 1848–1855.

    PubMed  CAS  Google Scholar 

  26. Maloum K, Pritsch O, Magnac C, et al. Expression of unmutated VH genes is a detrimental prognostic factor in chronic lymphocytic leukemia. Blood, 2000; 96: 377–379.

    PubMed  CAS  Google Scholar 

  27. Klein U, Tu Y, Stolovitzky GA, et al. Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells. J Exp Med 2001; 194: 1625–1638.

    Article  PubMed  CAS  Google Scholar 

  28. Rosenwald A, Alizadeh AA, Widhopf G, et al. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med 2001; 194: 1639–1647.

    Article  PubMed  CAS  Google Scholar 

  29. French Cooperative Group on Chronic Lymphocytic Leukemia. A randomized clinical trial of chlorambucil versus COP in stage B chronic lymphocytic leukemia. Blood 1990; 75: 1422–1425.

    Google Scholar 

  30. Catovsky D, Hamblin T, Richards S. Preliminary results of UK MRC trial in chronic lymphocytic leukemiaCLL3. In: Proceedings of the 27th Congress of the International Society of Haematology (ISH-EHA). Br J Haematol 1998;102:278, abstract 0–114.

    Google Scholar 

  31. Montserrat E, Alcala A, Parody R, et al. Treatment of chronic lymphocytic leukemia in advanced stages. A randomized trial comparing chlorambucil plus prednisone versus cyclophosphamide, vincristine, and prednisone. Cancer 1985; 56: 2369–2375.

    Article  PubMed  CAS  Google Scholar 

  32. Raphael B, Andersen JW, Silber R, et al. Comparison of chlorambucil and prednisone versus cyclophosphamide, vincristine, and prednisone as initial treatment for chronic lymphocytic leukemia: long-term follow-up of an Eastern Cooperative Oncology Group randomized clinical trial. J Clin Oncol 1991; 9: 770–776.

    PubMed  CAS  Google Scholar 

  33. Hester JP, Gehan EA. Cytoxan, adriamycin, prednisone (CAP) chemotherapy for chronic lymphocytic leukemia (abstract). Proc Am Soc Clin Oncol 1978; 19: 214.

    Google Scholar 

  34. Keating MJ, Scouros M, Murphy S, Kantarjian H, Hester J, McCredie KB, Hersh EM, Freireich EJ. Multiple agent chemotherapy (POACH) in previously treated and untreated patients with chronic lymphocytic leukemia. Leukemia 1988; 2: 157–164.

    PubMed  CAS  Google Scholar 

  35. Hansen MM, Andersen E, Birgens H, Christensen BE, Christensen TG, Geisler C. CHOP versus chlorambucil + prednisolone in chronic lymphocytic leukemia. Leuk Lymphoma 1991;(Suppl 4 ): 97–100.

    Google Scholar 

  36. Kimby E, Mellstedt H. Chlorambucil/prednisolone versus CHOP in symtomatic chronic lymphocytic leukemia of B-cell type. Leuk Lymphoma 1991;(suppl 4 ): 93–96.

    Google Scholar 

  37. Jaksic B, Brugiatelli M, Krc I, et al. High dose chlorambucil versus Binet’s modified cyclophosphamide, doxorubicin, vincristine, and prednisone regimen in the treatment of patients with advanced B-cell chronic lymphocytic leukemia. Results of an international multicenter randomized trial. International Society for ChemoImmunotherapy, Vienna. Cancer 1997; 79: 2107–2114.

    Article  PubMed  CAS  Google Scholar 

  38. French Cooperative Group on Chronic Lymphocytic Leukaemia. Effectiveness of “CHOP” regimen in advanced untreated chronic lymphocytic leukaemia. Lancet 1986; 1: 1346–1349.

    Google Scholar 

  39. French Cooperative Group on Chronic Lymphocytic Leukaemia. Long-term results of the CHOP regimen in stage C chronic lymphocytic leukaemia. Br J Haematol 1989; 73: 334–340.

    Google Scholar 

  40. French Cooperative Group on CLL. Is the CHOP regimen a good treatment for advanced CLL? Results from two randomized clinical trials. French Cooperative Group on Chronic Lymphocytic Leukemia. Leuk Lymphoma 1994; 13: 449–456.

    Google Scholar 

  41. Leporrier M, Chevret S, Cazin B, et al. Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients. Blood 2001; 98: 2319–2325.

    Article  PubMed  CAS  Google Scholar 

  42. Binet JL, Leporrier M, Dighiero G, et al. A clinical staging system for chronic lymphocytic leukemia. Prognostic significance. Cancer 1977; 40: 855–864.

    Article  PubMed  CAS  Google Scholar 

  43. Kempin S, Lee BJd, Thaler HT, et al. Combination chemotherapy of advanced chronic lymphocytic leukemia: the M-2 protocol (vincristine, BCNU, cyclophosphamide, melphalan, and prednisone). Blood 1982; 60: 1110–1121.

    PubMed  CAS  Google Scholar 

  44. Grever MR, Kopecky KJ, Coltman CA, et al. Fludarabine monophosphate: a potentially useful agent in chronic lymphocytic leukemia. Nouv Rev Fr Hematol 1988; 30: 457–459.

    PubMed  CAS  Google Scholar 

  45. Piro LD, Carrera CJ, Beutler E, Carson DA. 2-Chlorodeoxyadenosine: an effective new agent for the treatment of chronic lymphocytic leukemia. Blood 1988; 72: 1069–1073.

    PubMed  CAS  Google Scholar 

  46. Keating MJ, Kantarjian H, Talpaz M, et al. Fludarabine: a new agent with major activity against chronic lymphocytic leukemia. Blood 1989; 74: 19–25.

    PubMed  CAS  Google Scholar 

  47. O’Brien S, Kantarjian H, Beran M, et al. Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment [see comments]. Blood 1993; 82: 1695–1700.

    PubMed  Google Scholar 

  48. Keating MJ, O’Brien S, Lerner S, et al. Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy. Blood 1998; 92: 1165–1171.

    PubMed  CAS  Google Scholar 

  49. Byrd JC, Rai KR, Sausville EA, Grever MR. Old and new therapies in chronic lymphocytic leukemia: now is the time for a reassessment of therapeutic goals. Semin Oncol 1998; 25: 65–74.

    PubMed  CAS  Google Scholar 

  50. O’Brien SM, Kantarjian HM, Cortes J, et al. Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia. J Clin Oncol. 2001; 19: 1414–1420.

    PubMed  Google Scholar 

  51. Hallek M, Schmitt B, Wilhelm M, et al. Fludarabine plus cyclophosphamide is an efficient treatment for advanced chronic lymphocytic leukaemia (CLL): results of a phase II. Br J Haematol. 2001; 114 (2): 342–348.

    Article  PubMed  CAS  Google Scholar 

  52. Cazin B, Maloum K, Divine M, et al.. Oral fludarabine and cyclophosphamide in previously CLL Data on 59 patients (abstract). Blood 2001; 98 (Suppl I): 3214a.

    Google Scholar 

  53. Frewin R, Turner D, Tighe M, et al. Combination therapy with fludarabine and cyclophosphamide as salvage treatment in lymphoproliferative disorders. Br J Haematol. 1999; 104: 612–613.

    Article  PubMed  CAS  Google Scholar 

  54. Flinn IW, Byrd JC, Morrison C, et al. Fludarabine and cyclophosphamide with filgrastim support in patients with previously untreated indolent lymphoid malignancies. Blood 2000; 96: 71–75.

    PubMed  CAS  Google Scholar 

  55. Saven A, Piro LD. 2-Chlorodeoxyadenosine: a potent antimetabolite with major activity in the treatment of indolent lymphoproliferative disorders. Hematol Cell Ther 1996; 38: S93–101.

    PubMed  CAS  Google Scholar 

  56. Saven A, Lemon RH, Kosty M, Beutler E, Piro LD. 2-Chlorodeoxyadenosine activity in patients with untreated chronic lymphocytic leukemia. J Clin Oncol 1995; 13: 570–574.

    PubMed  CAS  Google Scholar 

  57. Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996; 87: 4990–4997.

    PubMed  CAS  Google Scholar 

  58. The French Cooperative Group on CLL, Johnson S, Smith AG, Loffler H, et al. Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. Lancet 1996; 347: 1432–1438.

    Google Scholar 

  59. Rai KR, Peterson BL, Appelbaum FR, et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia, N Engl J Med 2000; 343: 1750–1757.

    Article  PubMed  CAS  Google Scholar 

  60. Spriano M, Chiurazzi F, Liso V, Mazza P, Molica S, Gobbi M. Multicentre prospective randomized trial of fludarabine versu chlorambucil and prednisone in previously untreated patients with active B-CLL (abstract). In: Proceedings of the International Workshop on CLL. Paris, October 1999, p. 86.

    Google Scholar 

  61. Jaksic B, Delmer A, Brugiatelli M, et al. Interim analysis of a randomised EORTC study comparing high dose chlorambucil (HD-CLB) vs fludarabine (FAMP) in untreated B-cell chronic lymphocytic leukaemia (CLL). Hematol Cell Ther 1997; 39: S87.

    Google Scholar 

  62. Robak T, Blonski JZ, Kasznicki M, et al. Cladribine with prednisone versus chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia: report of a prospective, randomized, multicenter trial. Blood 2000; 96: 2723–2729.

    PubMed  CAS  Google Scholar 

  63. Riechmann L, Clark M, Waldmann H, Winter G. Reshaping human antibodies for therapy. Nature 1988; 332: 323–327.

    Article  PubMed  CAS  Google Scholar 

  64. Flynn JM, Byrd JC. Campath-1H monoclonal antibody therapy. Cur Opin Immunol 2000; 12: 574–581.

    CAS  Google Scholar 

  65. Osterborg A, Fassas AS, Anagnostopoulos A, et al. Humanized CD52 monoclonal antibody Campath- 1 H as first-line treatment in chronic lymphocytic leukaemia. Br J Haematol 1996; 93: 151–153.

    Article  PubMed  CAS  Google Scholar 

  66. Osterborg A, Dyer MJ, Bunjes D, et al. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia. J Clin Oncol 1997; 15: 1567–1574.

    PubMed  CAS  Google Scholar 

  67. Dyer MJ, Kelsey SM, Mackay HJ, et al. In vivo “purging” of residual disease in CLL with Campath-1H. Br J Haematol 1997; 97: 669–672.

    Article  PubMed  CAS  Google Scholar 

  68. Gilleece MH, Dexter TM. Effect of campath-1H antibody on human hematopoietic progenitors in vitro. Blood 1993; 82: 807–812.

    PubMed  CAS  Google Scholar 

  69. Bowen AL, Zomas A, Emmett E, Matutes E, Dyer MJ, Catovsky D. Subcutaneous Campath-1H in fludarabineresistant/relapsed chronic lymphocytic leukemia. Br J Haematol 1997; 96: 617–619.

    Article  PubMed  CAS  Google Scholar 

  70. Grillo-Lopez AJ, Hedrick E, Rashford M, Benyunes M. Rituximab: ongoing and future clinical development (review). Semin Oncol 2002; 29 (suppl 2): 105–112.

    Article  PubMed  CAS  Google Scholar 

  71. O’Brien SM, Kantarjian H, Thomas DA, et al. Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol 2001; 19: 2165–2170.

    PubMed  Google Scholar 

  72. Byrd JC, Murphy T, Howard RS, et al. Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol 2001; 19: 2153–2164.

    PubMed  CAS  Google Scholar 

  73. Kaminski MS, Estes J, Zasadny KR, et al. Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood 2000; 96: 1259–1266.

    PubMed  CAS  Google Scholar 

  74. Rai KR, Dohner H, Keating MJ, Montserrat E. Chronic lymphocytic leukemia: case-based session. Hematology (Am Soc Hematol Educ Program) 2001;Jan:140–156.

    Google Scholar 

  75. Michallet M, Corront B, Hollard D, et al. Allogeneic bone marrow transplantation in chronic lymphocytic leukemia: 17 cases. Report from the EBMTG, Bone Marrow Transplant 1991; 7: 275–279.

    PubMed  CAS  Google Scholar 

  76. Rabinowe SN, Soiffer RJ, Gribben JG, et al. Autologous and allogeneic bone marrow transplantation for poor prognosis patients with B-cell chronic lymphocytic leukemia. Blood. 1993; 82: 1366–1376.

    PubMed  CAS  Google Scholar 

  77. Khouri IF, Keating MJ, Vriesendorp HM. Autologous and allogeneic bone marrow transplantation for chronic lymphocytic leukemia: preliminary results. J Clin Oncol 1994; 12: 748–758.

    PubMed  CAS  Google Scholar 

  78. Michallet M, Archimbaud E, Bandini G, et al. HLA-identical sibling bone marrow transplantation in younger patients with chronic lymphocytic leukemia. European Group for Blood and Marrow Transplantation and the International Bone Marrow Transplant Registry. Ann Intern Med 1996; 124: 311–315.

    PubMed  CAS  Google Scholar 

  79. Michallet M, Thiebaut A, Dreger P, et al. Peripheral blood stem cell (PBSC) mobilization and transplantation after fludarabine therapy in chronic lymphocytic leukaemia (CLL): a report of the European Blood and Marrow Transplantation (EBMT) CLL subcommittee on behalf of the EBMT Chronic Leukaemias Working Party (CLWP). Br J Haematol 2000; 108: 595–601.

    Article  PubMed  CAS  Google Scholar 

  80. Dreger P, von Neuhoff N, Kuse R, et al. Early stem cell transplantation for chronic lymphocytic leukaemia: a chance for cure? Br J Cancer 1998; 77: 2291–2297.

    Article  PubMed  CAS  Google Scholar 

  81. Provan D, Bartlett-Pandite L, Zwicky C, et al. Eradication of polymerase chain reaction-detectable chronic lymphocytic leukemia cells is associated with improved outcome after bone marrow tranplantation. Blood 1996; 88: 2228–2235.

    PubMed  CAS  Google Scholar 

  82. Sutton L, Maloum K, Gonzalez H, et al. Autologous hematopoietic stem cell transplantation as salvage treatment for advanced B cell chronic lymphocytic leukemia. Leukemia 1998; 12: 1699–1707.

    Article  PubMed  CAS  Google Scholar 

  83. Giralt S, Estey E, Albitar M, et al. Engraftment of allogenic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft versus leukemia without myeloablative therapy. Blood 1997; 89: 4531–4536.

    PubMed  CAS  Google Scholar 

  84. Slavin S, Nagler A, Naparstek E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation xith lethal cytoreduction for the treatment of malignant and non malignant hematologic diseases. Blood 1998; 91: 756–763.

    PubMed  CAS  Google Scholar 

  85. Khouri IF, Keating M, Korbling M, Pet al. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol 1998; 16: 2817–2824.

    PubMed  CAS  Google Scholar 

  86. Lawrence JH, Low-Beer BVA, Carpender JWJ. Chronic lymphatic leukemia: study of 100 patients with radioactive phosphorus. JAMA 1949; 140: 585.

    Article  CAS  Google Scholar 

  87. Johnson RE: Total body irradiation of chronic lymphocytic leukemia. Cancer 1976; 37: 2691.

    Google Scholar 

  88. Chanana AD, Cronkite EP, Rai KR: The role of extracorporeal irradiation of blood in the treatment of leukemia. Int J Radiat Oncol Biol Phys 1976; 1: 539–548.

    Article  PubMed  CAS  Google Scholar 

  89. Richards F, Spurr CL, Ferree C, Blake DD, Raben M: The control of chronic lymphocytic leukemia with mediastinal irradiation. Am J Med 1978; 64: 947–954.

    Article  PubMed  Google Scholar 

  90. Ferrant A, Michaux JL, Sokal G. Splenectomy in advanced chronic lymphocytic leukemia. Cancer 1986; 58: 2130–2696.

    Article  PubMed  CAS  Google Scholar 

  91. Stein RS, Weikert D, Reynols V Greer JP, Flexner JM: Splenectomy for end-stage chronic lymphocytic leukemia. Cancer 1987; 59: 1815–1818.

    Article  PubMed  CAS  Google Scholar 

  92. Delpero JR, Mouvenaeghel G, Gastaut JA, et al. Splenectomy for hypersplenism in chronic lymphocytic leukemia and malignant non-Hodgkin’s lymphoma. Br J Surg 1990; 77: 443–449.

    Article  PubMed  CAS  Google Scholar 

  93. Hsu FJ, Caspar CB, Czerwinski D, et al. Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma—long-term results of a clinical trial. Blood 1997; 89: 3129–3135.

    PubMed  CAS  Google Scholar 

  94. Kipps TJ. Future strategies toward the cure of indolent B-cell malignancies. Molecular genetic approaches. Semin Hematol 1999; 36: 3–8.

    PubMed  CAS  Google Scholar 

  95. Cheson BD. Emerging therapies and future directions in chronic lymphocytic leukaemia-chemotherapy. Hematol Cell Ther 2000; 42 (1): 41–47.

    Article  PubMed  CAS  Google Scholar 

  96. Cooperative Group for the Study of Immunoglobulin in Chronic Lymphocytic Leukemia. Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia. A randomized control trial. N Engl J Med 1988; 319: 902–907.

    Google Scholar 

  97. Dighiero G, Binet JL. When and how to treat chronic lymphocytic leukemia. N Engl J Med 2000; 343: 1799–1802.

    Article  PubMed  CAS  Google Scholar 

  98. Hansen MM. Chronic lymphocytic leukaemia. Clinical studies based on 189 cases followed for a long time. Scand J Haematol 1973;(suppl 18 ): 3–286.

    Google Scholar 

  99. Lim LC, Koh LP, Tan P. Fatal cytokine release syndrome with chimeric anti-CD20 monoclonal antibody rituximab in a 71-year-old patient with chronic lymphocytic leukemia. J Clin Oncol 1999; 17: 1962–1963.

    PubMed  CAS  Google Scholar 

  100. Yang H, Rosove MH, Figlin RA. Tumor lysis syndrome occurring after the administration of rituximab in lymphoproliferative disorders: high-grade non-Hodgkin’s lymphoma and chronic lymphocytic leukemia. Am J Hematol 1999; 62: 247–250.

    Article  PubMed  CAS  Google Scholar 

  101. Winkler U, Jensen M, Manzke O, Schulz H, Diehl B, Engert A. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). Blood 1999; 94: 2217–2224.

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. Guillaume Dighiero MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Section of Hematology/Oncology, Veterans Affairs Medical Center, Augusta, GA, USA

    Guy B. Faguet MD

Rights and permissions

Reprints and permissions

Copyright information

© 2004 Springer Science+Business Media New York

About this chapter

Cite this chapter

Dighiero, G. (2004). Guidelines for Clinical Management of CLL. In: Faguet, G.B. (eds) Chronic Lymphocytic Leukemia. Contemporary Hematology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-412-2_12

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-412-2_12

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-61737-355-8

  • Online ISBN: 978-1-59259-412-2

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation